DAMORA THERAPEUTICS INC (DMRA)
NASDAQHealth CareBiotechnologySnapshot 2026-07-07
$30.00+0.67%
Close 2026-07-07 · 1-day change
Reading DMRA? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track DMRA free→NASDAQHealth CareBiotechnologySnapshot 2026-07-07
Reading DMRA? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track DMRA free→QuarterlyIQ Insights · DMRA
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(6.9) + peer(0.2*0.0) + term(0.0) → 2.4% (capped ±15.0)
Calibrated likelihood the company misses analyst consensus on its next print, read from its own miss history plus its industry base rate. A fundamental tilt, not a price call — and a quiet watch-flag, not an alarm.
Elevated risk of a next-quarter earnings miss: this name has erratic recent earnings surprises and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Calibrated. Base rate ~24%.
Consecutive quarters it missed, most recent run.
How often this industry misses, baseline.
Industry peers that missed in the recent window.
in 27 days
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Provisional scorecard: fewer than 4 guided quarters in the corpus.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition. On March 9, 2026, Damora Therapeutics, Inc., formerly known as Galecto, Inc. (the “Company”), issued a press release announcing, among other things, the Name Change Amendment (as defined below) and the Symbol Change (as defined below), which indicates that the Company had cash and cash equivalents of approximately $535 million as of February 28, 2026. The estimated cash and cash equivalents amount is preliminary and unaudited, represents manageme…
Results of Operations and Financial Condition. As of December 31, 2022, Galecto, Inc.’s (the "Registrant") cash, cash equivalents and investments balance was approximately $66 million.
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.